FDA Quietly Greenlights GLAS Vape – Five Years After PMTA Submission

---

Key Points:

• FDA Authorization: On March 12, 2026, the U.S. Food and Drug Administration issued two marketing granted orders (MGOs) allowing California-based Glas Inc. to market the GLAS G Device and GLAS Blonde Tobacco Pod through the PMTA pathway.

• Quiet Approval: The authorization appeared only as an update to the FDA’s authorized product list and was issued without the press release that typically accompanies such decisions.

• Authorized Products: The orders cover a closed-system vaping device and a tobacco-flavored cartridge containing 1.2 mL of e-liquid with 50 mg/mL nicotine strength.

• Public Health Determination: The FDA concluded the products are “appropriate for the protection of public health” (APPH) after reviewing stability, chemistry, and toxicological evidence.

• Youth Mitigation Plan: Glas Inc. committed to marketing restrictions including age-gated online sales, advertising limited to licensed retailers, restricted social media marketing, and avoidance of influencer promotions.

• Post-Market Oversight: Like all PMTA-authorized products, the company must submit annual reports on marketing, sales, demographics, adverse events, and scientific studies, while maintaining records for at least four years.

• Lengthy Approval Process: Glas Inc. first submitted its PMTA in July 2021, meaning the authorization came nearly five years after the initial application.

• Regulatory Delays: The company responded to multiple FDA information requests and formally raised concerns in January 2026 about what it described as an “unreasonable delay” in the agency’s review.

• Limited Product Authorizations: As of March 2026, the FDA has authorized only a small number of e-cigarette products, all in tobacco or menthol flavors, while denying millions of flavored product applications.

• Youth Flavor Data: According to the CDC’s 2023 National Youth Tobacco Survey, only 6.4 percent of youth who vape reported using tobacco-flavored products.

• Adult Use Trends: In 2024, more than 21.3 million American adults were current e-cigarette users.

• Year-Over-Year Growth: Adult vaping increased 3.9 percent from 2023, representing about 1 million additional adult users in a single year.

• Long-Term Growth: Since 2016, adult vaping has increased 70.2 percent, equating to more than 9.6 million additional adult users.

• Adult Demographics: Among adult e-cigarette users, 51.1 percent were between the ages of 35 and 44, indicating significant adoption among middle-aged adults.

• Combustion vs. Nicotine: Decades of research show that the primary harms of smoking come from combustion rather than nicotine itself.

• Reduced Toxic Exposure: E-cigarettes heat liquid rather than burn tobacco, producing far fewer toxic chemicals than combustible cigarette smoke.

• International Harm Reduction Policies: Public health authorities in the United Kingdom, Canada, and New Zealand recognize vaping as a significantly less harmful alternative to smoking.

• UK Harm Reduction Leadership: Public Health England and the Royal College of Physicians conclude that vaping is substantially less harmful than smoking, and the UK now provides vaping kits to smokers seeking to quit.

• Adult vs Youth Use: Recent survey data show that adult vaping now exceeds youth vaping, reinforcing the role of these products as tools used primarily by adults.

• Bottom Line: The FDA’s authorization of Glas Inc.’s products represent a positive step for independent manufacturers, but the slow pace of the PMTA process continues to limit access to regulated harm reduction products for more than 21 million American adults who vape.

---

The U.S. Food and Drug Administration recently updated its list of authorized e-cigarette products, quietly allowing the marketing of a new vapor product manufactured by an independent company – without issuing the press release that typically accompanies such decisions. While permitting the sale of tobacco harm reduction products is a welcome development, the agency’s muted announcement highlights the continued tension between expanding adult access to safer alternatives and the FDA’s long-standing regulatory caution toward vaping products.

On March 12, 2026, the FDA issued two marketing granted orders (MGOs) under the Premarket Tobacco Product Application (PMTA) pathway for products manufactured by California-based Glas Inc., a privately owned company founded in 2014. The authorization covers two products: the GLAS G Device, a closed-system electronic cigarette, and the GLAS Blonde Tobacco Pod, a tobacco-flavored cartridge designed for use with the device containing 1.2 milliliters of e-liquid at a nicotine strength of 50 milligrams per milliliter.

In issuing the orders, the FDA determined that permitting the marketing of the products is “appropriate for the protection of public health” (APPH). The agency noted that the manufacturer provided sufficient evidence supporting the chemical and microbial stability of the products for 32 weeks, which contributed to the determination that the products could benefit adult smokers while accounting for potential risks to non-users, including youth.

The order also recognizes several elements of Glas Inc.’s marketing plan intended to limit youth exposure and access. These measures include avoiding advertising in consumer-facing print publications, restricting point-of-sale advertising to licensed tobacco retailers, implementing age-gated online sales and marketing, requiring age verification to access the company’s website, and limiting social media advertising to adults – specifically Instagram users aged 25 to 54. The FDA also recommended additional precautions, such as avoiding the use of influencers or brand ambassadors and limiting sponsorships to events restricted to individuals aged 21 and older.

As with all products authorized through the PMTA process, Glas Inc. must comply with extensive post-market reporting and record-keeping requirements. These obligations include submitting annual reports to the FDA detailing labeling and marketing materials, sales and distribution data, purchaser demographics, adverse health events, manufacturing changes, and any ongoing or completed scientific studies. The company must also retain records related to manufacturing, stability monitoring, complaints, advertising, and distribution for several years, generally at least four years.

Although the authorization represents progress, the timeline highlights the challenges facing independent manufacturers seeking FDA approval. Glas Inc. first submitted its PMTA to the agency in July 2021. Over the following years, the company responded to multiple FDA information requests and deficiency letters. In January 2026 – nearly five years after its initial submission – the company formally raised concerns about what it described as an “unreasonable delay” in the agency’s review.

The lengthy review process is particularly notable given that the authorized product is tobacco-flavored. According to the Centers for Disease Control and Prevention’s National Youth Tobacco Survey, among middle and high school students who reported past-month e-cigarette use in 2023, only 6.4 percent reported using tobacco-flavored products.

To date, the FDA has focused heavily on youth use in evaluating PMTAs for vapor products. As of March 2026, the agency has issued marketing orders for only a limited number of e-cigarette products, all in tobacco or menthol flavors, while denying millions of applications for flavored products citing youth appeal.

While youth use of flavored products has been widely discussed, adults also use flavored alternatives – and youth vaping has declined significantly in recent years. Restricting adult access to reasonably regulated alternatives years after manufacturers submit applications undermines the potential of harm reduction for millions of smokers seeking less harmful options.

According to the Centers for Disease Control and Prevention’s Behavioral Risk Factor Surveillance System, more than 21.3 million American adults aged 18 or older were current e-cigarette users. This represents a 3.9 percent increase from 2023, when 7.7 percent of adults reported vaping, and equates to approximately 1 million additional adult vapers in a single year. Adult vaping has also grown substantially over the past decade. Since 2016, when 4.7 percent of U.S. adults used e-cigarettes, adult vaping has increased by 70.2 percent, representing more than 9.6 million additional adult users. Notably, among adult e-cigarette users in 2024, more than half (51.1 percent) were between the ages of 35 and 44.

Decades of research have made clear that the primary harms of tobacco use come from combustion rather than nicotine itself. Combustible cigarettes contain hundreds of ingredients and produce thousands of chemicals when burned – 69 which are known carcinogens. By contrast, e-cigarettes heat a liquid solution containing a small number of ingredients, producing an aerosol with significantly fewer toxic compounds than cigarette smoke.

Public health authorities in several countries have recognized the potential of vaping products as a harm-reduction tool for adults who smoke. The United Kingdom has been a global leader in this area, with Public Health England concluding that vaping products are substantially less harmful than smoking and may help reduce smoking-related disease and death. The Royal College of Physicians has similarly concluded that the long-term health risks of e-cigarettes are unlikely to exceed a small fraction of the risks associated with combustible tobacco use. In recent years, the United Kingdom has even launched programs providing vaping kits to smokers seeking to quit.

Other countries have reached similar conclusions. Health Canada has acknowledged that completely switching from smoking to vaping is less harmful, while New Zealand’s Ministry of Health has stated that vaping is significantly less harmful than smoking tobacco.

Notably, recent data show that adult use of e-cigarettes now exceeds youth use, with 8 percent of U.S. adults vaping in 2024, compared to 5.9 of youth. Policies should reflect this trend, particularly given that many adult users are former smokers or individuals who might otherwise have continued smoking in the absence of lower-risk alternatives.

The FDA’s authorization of Glas Inc.’s products is a positive step, particularly as it represents approval for a product developed by an independent manufacturer. However, the pace of the PMTA process remains far too slow. For the more than 21 million American adults who rely on vapor products as an alternative to cigarettes, the FDA must accelerate the authorization of additional products that meet the agency’s public-health standard.

Nothing in this analysis is intended to influence the passage of legislation, and it does not necessarily represent the views of Tobacco Harm Reduction 101.